FMO5 and metabolic syndrome: HGF has been reported to play a role in reducing dyslipidemia associated with steatohepatitis and improving the outcomes of chronic liver injury by increasing production of antioxidant proteins and suppressing NAPDH oxidase to reduce ROS, thus, preventing hepatocyte apoptosis and subsequent liver damage18–21.